Sales of SEK 941 (905) million, an increase of 4% in local currencies and 4% in SEK.
GOTHENBURG, Sweden, April 18, 2024 /PRNewswire/ -- nnFirst quarter nnSales of SEK 841 (854) million, a flat growth in local currencies and a decrease of 2% in SEK. nSales per region, in local currencies was +19% in APAC, -2% in EMEA and -14% in Americas. nSales per business area, in local currencies was +12% in Consumables, +8% in Technologies and -12% in Genetics. nGross margin increased to 57.1% (56.8). nOperating income before depreciation and amortisation (EBITDA) increased to SEK 272 (262) million, giving an EBITDA margin of 32.4% (30.6). nOperating cash flow increased to SEK 198 million (160). nNet income was SEK 115 (99) million, resulting in earnings per share of SEK 0.85 (0.74). nThe product area Genomics was previously reported in Consumables business area but is now part of Genetic Services business area, renamed to Genetics business area.
GOTHENBURG, Sweden, March 30, 2023 /PRNewswire/ -- Vitrolife Group has today published its Annual and Sustainability Report for 2022.
GÖTEBORG, Sweden, Nov. 25, 2021 /PRNewswire/ -- Vitrolife AB (publ) today announced that it will be expanding its distribution of genomic testing kits to the Asia Pacific region (excluding China) in accordance with the Illumina partnership agreement announced in October 2018. The expansion of the territory follows the commercial launch of EmbryoMap during Q2 of this year and requires a payment of USD 3 million (approximately SEK 27 million) to Illumina for the expanded rights. EmbryoMap has been developed by Vitrolife for use on Illumina sequencing instruments.